
Rainer Sabatowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8247907/publications.pdf Version: 2024-02-01



PAINED SABATOWSKI

#	Article	IF	CITATIONS
1	C-tactile touch perception in patients with chronic pain disorders. Pain Reports, 2021, 6, e941.	2.7	5
2	C-tactile touch perception in migraineurs – a case-control study. Cephalalgia, 2020, 40, 478-492.	3.9	4
3	The prevalence of headache in German pupils of different ages and school types. Cephalalgia, 2019, 39, 1030-1040.	3.9	19
4	Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. Pain, 2018, 159, 673-683.	4.2	86
5	Multimodal pain therapy in chronic noncancer pain—gold standard or need for further clarification?. Pain, 2017, 158, 1853-1859.	4.2	67
6	Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients – subgroup analyses from three European clinical trials. Current Medical Research and Opinion, 2017, 33, 595-603.	1.9	13
7	Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis – A Multi-perspective Consensus Study. Zeitschrift Fur Orthopadie Und Unfallchirurgie, 2017, 155, 539-548.	0.7	46
8	A multicenter study of attitudinal barriers to cancer pain management. Supportive Care in Cancer, 2017, 25, 3595-3602.	2.2	39
9	Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliative Medicine, 2017, 31, 26-34.	3.1	46
10	Multimodale Schmerztherapie. , 2017, , 381-390.		0
11	Core Outcome Sets and Multidimensional Assessment Tools for Harmonizing Outcome Measure in Chronic Pain and Back Pain. Healthcare (Switzerland), 2016, 4, 63.	2.0	13
12	Validation and application of a core set of patient-relevant outcome domains to assess the effectiveness of multimodal pain therapy (VAPAIN): a study protocol. BMJ Open, 2015, 5, e008146-e008146.	1.9	29
13	Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids. Clinical and Translational Gastroenterology, 2015, 6, e90.	2.5	24
14	Cross-cultural adaptation, evaluation and validation of the Spouse Response Inventory: a study protocol. BMJ Open, 2014, 4, e005119.	1.9	1
15	Opioids and Driving Ability: Current Data do not Support One Opioid Being More Favorable Than Another. Pain Practice, 2014, 14, 196-197.	1.9	6
16	Assessing Cognitive and Psychomotor Performance in Patients with Fibromyalgia Syndrome. Pain and Therapy, 2014, 3, 85-101.	3.2	15
17	Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial. Pain and Therapy, 2014, 3, 17-29.	3.2	14
18	Dose or content? Effectiveness of pain rehabilitation programs for patients with chronic low back pain: A systematic review. Waterschoot et al., Pain 155 (2014) 179–189. Pain, 2014, 155, 1903-1904.	4.2	6

RAINER SABATOWSKI

#	Article	IF	CITATIONS
19	Sustained Safety and Efficacy of Onceâ€Daily Hydromorphone Extendedâ€Release (OROS [®]) Ţ Patients with Moderate to Severe Chronic Noncancer Pain. Pain Practice, 2013, 13, 30-40.	j ETQq1 1 0 1.9	.784314 rgB ⁻ 16
20	Multidisciplinary pain management programs. Journal of Pain Research, 2013, 6, 355.	2.0	10
21	Increase in Opiate Prescription in Germany Between 2000 and 2010. Deutsches Ärzteblatt International, 2013, 110, 45-51.	0.9	128
22	In Reply. Deutsches Ärzteblatt International, 2013, 110, 402.	0.9	0
23	Ask The Experts: Critical issues in cancer pain management. Pain Management, 2012, 2, 201-204.	1.5	1
24	Systematic Review of the Quality and Generalizability of Studies on the Effects of Opioids on Driving and Cognitive/Psychomotor Performance. Clinical Journal of Pain, 2012, 28, 542-555.	1.9	70
25	Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Current Medical Research and Opinion, 2012, 28, 911-936.	1.9	71
26	Practicability, safety, and efficacy of a "German model―for opioid conversion to oral levo-methadone. Supportive Care in Cancer, 2012, 20, 2105-2110.	2.2	15
27	Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Current Medical Research and Opinion, 2012, 28, 1337-1346.	1.9	29
28	Utilisation of transdermal fentanyl in Germany from 2004–2006 by Edeltraut Garbe and colleagues. Pharmacoepidemiology and Drug Safety, 2012, 21, 902-903.	1.9	1
29	The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug and Alcohol Dependence, 2011, 117, 190-197.	3.2	32
30	Microcurrent Transcutaneous Electric Nerve Stimulation in Painful Diabetic Neuropathy: A Randomized Placebo-Controlled Study. Pain Medicine, 2011, 12, 953-960.	1.9	41
31	Preoperative chronic pain in radical prostatectomy patients: preliminary evidence for enhanced susceptibility to surgically induced pain. European Journal of Anaesthesiology, 2010, 27, 448-454.	1.7	20
32	Chronic Pain and Disability After Pelvic and Acetabular Fractures—Assessment With the Mainz Pain Staging System. Journal of Trauma, 2010, 69, 128-136.	2.3	50
33	A Randomized Study to Demonstrate Noninferiority of Once-Daily OROS® Hydromorphone with Twice-Daily Sustained-Release Oxycodone for Moderate to Severe Chronic Noncancer Pain. Pain Practice, 2010, 10, 404-415.	1.9	34
34	Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. Pain Practice, 2010, 10, 428-450.	1.9	244
35	Risk factors for acute and chronic postoperative pain in patients with benign and malignant renal disease after nephrectomy. European Journal of Pain, 2009, 13, 853-860.	2.8	87
36	Preoperative pain as a risk factor for chronic postâ€surgical pain – Six month followâ€up after radical prostatectomy. European Journal of Pain, 2009, 13, 1054-1061.	2.8	75

RAINER SABATOWSKI

#	Article	IF	CITATIONS
37	Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Current Medical Research and Opinion, 2009, 25, 1295-1305.	1.9	83
38	Prevalence, severity, and chronicity of pain and general healthâ€related quality of life in patients with localized prostate cancer. European Journal of Pain, 2008, 12, 339-350.	2.8	46
39	A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl Patch Compared to Standard Opioid Treatment in Cancer Pain. Journal of Pain and Symptom Management, 2008, 36, 268-279.	1.2	43
40	Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Current Medical Research and Opinion, 2007, 23, 2333-2345.	1.9	24
41	Assessing Cognitive and Psychomotor Performance Under Long-Term Treatment with Transdermal Buprenorphine in Chronic Noncancer Pain Patients. Anesthesia and Analgesia, 2007, 105, 1442-1448.	2.2	47
42	Pain Prevalence in Hospitalized Patients in a German University Teaching Hospital. Journal of Pain and Symptom Management, 2005, 29, 498-506.	1.2	137
43	Switching from Reservoir to Matrix Systems for the Transdermal Delivery of Fentanyl: A Prospective, Multicenter Pilot Study in Outpatients with Chronic Pain. Journal of Pain and Symptom Management, 2005, 30, 289-297.	1.2	41
44	Pregabalin in Postherpetic Neuralgia. Drugs, 2005, 65, 119-120.	10.9	4
45	Electronic pain diary: a randomized crossover study. Journal of Pain and Symptom Management, 2004, 28, 259-267.	1.2	102
46	Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain, 2004, 109, 26-35.	4.2	478
47	Driving Ability Under Long-Term Treatment with Transdermal Fentanyl. Journal of Pain and Symptom Management, 2003, 25, 38-47.	1.2	88
48	Validation of the German Version of the Brief Fatigue Inventory. Journal of Pain and Symptom Management, 2003, 25, 449-458.	1.2	116
49	Analysis and treatment of different types of neuropathic cancer pain. Journal of Pain and Symptom Management, 2003, 26, 1123-1131.	1.2	45
50	Encapsulation of an intrathecal catheter. Pain, 2003, 103, 217-220.	4.2	5
51	Mu-Opioid Receptor mRNA Regulation During Morphine Tolerance in the Rat Peripheral Nervous System. Anesthesia and Analgesia, 2003, 97, 1458-1463.	2.2	18
52	Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine. Journal of Pain and Symptom Management, 2002, 23, 3-5.	1.2	56
53	Germany. Journal of Pain and Symptom Management, 2002, 24, 183-187.	1.2	23
54	A randomized crossover trial of IV fluid replacement versus no fluid replacement in autologous blood donors with cardiovascular disease. Transfusion, 2002, 42, 226-231.	1.6	3

RAINER SABATOWSKI

#	Article	IF	CITATIONS
55	Patients' associations with regard to analgesic drugs and their forms for application – a pilot study. Supportive Care in Cancer, 2002, 10, 480-485.	2.2	12
56	Failure of Autologous Fresh Frozen Plasma to Reduce Blood Loss and Transfusion Requirements in Coronary Artery Bypass Surgery. Anesthesiology, 2001, 95, 81-86.	2.5	28
57	Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliative Medicine, 2001, 15, 309-321.	3.1	88
58	Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliative Medicine, 2000, 14, 111-119.	3.1	124
59	Cognitive impairment and its influence on pain and symptom assessment in a palliative care unit: development of a Minimal Documentation System. Palliative Medicine, 2000, 14, 266-276.	3.1	69
60	High-Dose Tramadol in Comparison to Low-Dose Morphine for Cancer Pain Relief. Journal of Pain and Symptom Management, 1999, 18, 174-179.	1.2	98
61	Validation of the German Version of the Brief Pain Inventory. Journal of Pain and Symptom Management, 1999, 18, 180-187.	1.2	297
62	Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain, 1999, 79, 15-20.	4.2	184